Production of isomalto-oligosaccharides with tailored technological and nutritional functionalities

生产具有定制技术和营养功能的异麦芽低聚糖

• 批准号: 542301-2019
• 负责人: Gänzle, Michael
• 金额: $ 8.01万
• 依托单位: University of Alberta
• 依托单位国家: 加拿大
• 项目类别: Collaborative Research and Development Grants
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=692954
• 关键词: Production; isomalto; oligosaccharides; tailored; technological

Isomalto-oligosaccharides (IMO) are used as alternative low-calorie sweeteners in food products. Because of different methods of production and downstream purification, commercial IMO differ substantially with regards to their composition, and thus in digestibility, caloric content and utilisation by intestinal microbiota. The IMO preparation produced by BioNeutra contains isomaltose and higher a(1?6)-linked isomalto-oligosaccharides as well as panose-series oligosaccharides with a degree of polymerization of 4 - 6. IMO are partially indigestible and the undigested portion is fermented in the colon. However, current knowledge does not allow to quantify the digestible portion of isomalto-oligosaccharides and hence their caloric value; moreover, the dietary fibre content of current IMO preparations as determined by official methods is relatively low, which negatively impacts marketing claims with respect to their nutritional functionality. It is therefore the aim of this project to develop novel methods for IMO production to decrease the digestibility, and to increase the fibre content. Novel oligosaccharides will be evaluated with respect to their digestibility and with respect to their use in food applications. The project aims to meet the following specific objectives: (i) To produce IMO with increased degree of polymerization and branching, and reduced digestibility. (ii) To characterize novel IMO with instrumental and enzymatic methods. (iii) To evaluate the digestibility of IMO in animal models. The long term aim is to establish a platform for flexible production of isomalto-oligosaccharides with tailored technological and nutritional functionalitiesBioNeutra Inc. will benefit by establishment of improved methods for production of IMO. Moreover, scientific support for functional claims for IMO is critical for BioNeutra's efforts to enhance market access in North America and in Europe. The project will support long term manufacturing employment in Canada.

异构体 - 寡糖（IMO）用作食品中的替代低热量甜味剂。由于生产和下游纯化方法，商业IMO在其组成方面有很大差异，因此在肠道微生物群中的消化率，热量含量和利用方面有所不同。由Bioneutra生产的IMO制剂含有异构体和较高的A（1？6）连接的异构性异构含糖以及悬sos-series寡糖，其聚合度为4-6。imo的一定程度，IMO是部分土著，无含水量的部分，并且在结肠元中被发酵。但是，当前的知识不允许量化异构体 - 寡糖的易消化部分，因此它们的热量值。此外，由官方方法确定的当前IMO制剂的饮食纤维含量相对较低，这对营养功能的营销主张产生了负面影响。因此，该项目的目的是为IMO生产开发新的方法以降低消化率并增加纤维含量。新型的寡糖将根据其消化率以及在食品应用中的使用方面进行评估。该项目旨在满足以下特定目标：（i）生产具有增加程度的聚合和分支的IMO，并降低了消化率。 （ii）用仪器和酶促方法表征新型IMO。 （iii）评估动物模型中IMO的消化率。长期的目的是建立一个通过量身定制的技术和营养功能性的平台，以灵活生产异构体寡糖Bioneutra Inc.将通过建立改进的IMO生产方法而受益。此外，对IMO的功能性主张的科学支持对于Bioneutra为增强北美和欧洲市场获得的努力至关重要。该项目将支持加拿大的长期制造业工作。